ReviveMed is a precision-medicine platform that leverages the data from small molecules or metabolites. Metabolomics (which is the study of small molecules such as glucose or cholesterol) is essential for developing the right therapeutics for the right patients. However, because identifying a large set of metabolites for each patient is costly and slow, metabolomic data has been under-utilized – until now!
ReviveMed technology, which was developed at MIT and published in Nature Methods, uniquely overcomes the difficulty of using a large set of metabolomic data, and transform these data into actionable insight. Currently, we are working with a few strategic partners from leading pharma/biotech companies, while developing our own metabolomic based therapeutics.